STK3

Serine/threonine-protein kinase 3

68,692 patent compounds predicted against STK3, 48,788 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL336612	0.52	8/20
SCHEMBL231766	0.79	6/20
SCHEMBL232042	1.00	5/20
SCHEMBL234334	1.00	5/20
Linifanib (SCHEMBL93804)	1.00	4/20
Ucn-01 (SCHEMBL259162)	1.00	4/20
SCHEMBL233442	0.75	4/20
SCHEMBL147422	0.66	4/20
SCHEMBL144979	0.56	4/20
SCHEMBL147381	0.50	4/20
SCHEMBL95142	1.00	3/20
Tofacitinib (SCHEMBL322753)	1.00	3/20
SCHEMBL143765	0.82	3/20
SCHEMBL145998	0.82	3/20
SCHEMBL232936	0.79	3/20
SCHEMBL233874	0.79	3/20
SCHEMBL94964	0.79	3/20
SCHEMBL353500	0.75	3/20
SCHEMBL147845	0.73	3/20
SCHEMBL142970	0.72	3/20

Germline variants in STK3 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full STK3 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to STK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation	PHASE4	ACTIVE_NOT_RECRUITING
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER	PHASE2/PHASE3	RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations	PHASE2	COMPLETED
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.	PHASE2	ACTIVE_NOT_RECRUITING
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors	PHASE1	RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	PHASE1	ACTIVE_NOT_RECRUITING
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
New Genes in the Carcinogenesis of Colorectal Cancer	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a STK3 binder may also engage these)

Protein	Name	Similarity
Q9JI10	—	1.000	Q9JI10 →
Q6IP06	—	1.000	Q6IP06 →
A4K2M3	—	1.000	A4K2M3 →
A4K2Y1	—	1.000	A4K2Y1 →
Q5E9L6	—	1.000	Q5E9L6 →
O54748	—	1.000	O54748 →
A4K2W5	—	1.000	A4K2W5 →
A4K2Q5	—	1.000	A4K2Q5 →
A4K2T0	—	1.000	A4K2T0 →
A4K2P5	—	1.000	A4K2P5 →
Q802A6	—	1.000	Q802A6 →
Q9JI11	—	1.000	Q9JI11 →
Q5ZJK4	—	1.000	Q5ZJK4 →
STK4	Serine/threonine-protein kinase 4	1.000	landscape →
Q7ZUQ3	—	0.999	Q7ZUQ3 →
A4K2S1	—	0.998	A4K2S1 →
Q9NB31	—	0.996	Q9NB31 →
Q6P3Q4	—	0.993	Q6P3Q4 →
Q6PA14	—	0.993	Q6PA14 →
PAK3	Serine/threonine-protein kinase PAK 3	0.992	landscape →
A8XJW8	—	0.991	A8XJW8 →
P35465	—	0.991	P35465 →
Q08E52	—	0.990	Q08E52 →
O61125	—	0.990	O61125 →
PAK2	Serine/threonine-protein kinase PAK 2	0.990	landscape →
O88643	—	0.989	O88643 →
Q7YQL4	—	0.988	Q7YQL4 →
Q7YQL3	—	0.988	Q7YQL3 →
Q8AXB4	—	0.988	Q8AXB4 →
Q8CIN4	—	0.987	Q8CIN4 →